tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TRVI Stock Latest News

Trevi Therapeutics: Optimism Amid Earnings Call Insights
Company AnnouncementsTrevi Therapeutics: Optimism Amid Earnings Call Insights
1d ago
TRVI
Promising Developments and Strategic Expansion Bolster Trevi Therapeutics’ Growth Potential
PremiumRatings
Promising Developments and Strategic Expansion Bolster Trevi Therapeutics’ Growth Potential
3d ago
TRVI
Trevi Therapeutics price target lowered to $27 from $29 at Raymond James
PremiumThe Fly
Trevi Therapeutics price target lowered to $27 from $29 at Raymond James
6d ago
TRVI
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics
PremiumRatings
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics
6d ago
TRVI
Trevi Therapeutics Reports Positive Trial Results and Financial Stability
PremiumCompany Announcements
Trevi Therapeutics Reports Positive Trial Results and Financial Stability
6d ago
TRVI
Trevi Therapeutics reports Q2 EPS (9c), consensus (10c)
PremiumThe FlyTrevi Therapeutics reports Q2 EPS (9c), consensus (10c)
6d ago
TRVI
Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald
1M ago
TRVI
Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald
1M ago
TRVI
Trevi Therapeutics Stockholders Approve Key Amendments
PremiumCompany Announcements
Trevi Therapeutics Stockholders Approve Key Amendments
2M ago
8K
TRVI
Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating
PremiumRatings
Trevi Therapeutics: Positive Developments and Financial Strength Support Buy Rating
2M ago
TRVI
Trevi Therapeutics Announces Public Offering Pricing
PremiumCompany Announcements
Trevi Therapeutics Announces Public Offering Pricing
2M ago
8K
TRVI
Trevi Therapeutics 17.4M share Secondary priced at $5.75
PremiumThe Fly
Trevi Therapeutics 17.4M share Secondary priced at $5.75
2M ago
TRVI
Promising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential
PremiumRatingsPromising Phase 2b Results for Haduvio in IPF-CC Drive Buy Rating and Highlight Market Potential
2M ago
TRVI
Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC
Premium
Ratings
Buy Rating for Trevi Therapeutics: Promising Phase 2b Results for Haduvio in IPF-CC
2M ago
TRVI
Closing Bell Movers: Credo Technology jumps 11% on earnings
Premium
The Fly
Closing Bell Movers: Credo Technology jumps 11% on earnings
2M ago
MRK
NUE
Trevi Therapeutics Terminates ATM Prospectus with Leerink
PremiumCompany Announcements
Trevi Therapeutics Terminates ATM Prospectus with Leerink
2M ago
8K
TRVI
Trevi Therapeutics price target raised to $23 from $20 at Oppenheimer
PremiumThe Fly
Trevi Therapeutics price target raised to $23 from $20 at Oppenheimer
2M ago
TRVI
Trevi Therapeutics announces $100M common stock offering
PremiumThe Fly
Trevi Therapeutics announces $100M common stock offering
2M ago
TRVI
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
PremiumRatings
Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Market Opportunities
2M ago
TRVI
Trevi Therapeutics Reports Positive Phase 2b Trial Results
PremiumCompany AnnouncementsTrevi Therapeutics Reports Positive Phase 2b Trial Results
2M ago
8K
TRVI
Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio
Premium
The Fly
Trevi Therapeutics says ‘positive’ results from Phase 2b CORAL trial of Haduvio
2M ago
TRVI
Trevi Therapeutics’ Strong Market Potential and Revenue Opportunities Highlighted in Buy Rating
Premium
Ratings
Trevi Therapeutics’ Strong Market Potential and Revenue Opportunities Highlighted in Buy Rating
3M ago
TRVI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >